Cargando…

Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non‐small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non‐negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Liang, Bai, Lianwei, Liu, Xianhong, Liu, Ying, Li, Shuang, Liu, Jingjing, Zhang, Shuang, Yang, Changliang, Ren, Xiubao, Cheng, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180579/ https://www.ncbi.nlm.nih.gov/pubmed/32134200 http://dx.doi.org/10.1111/1759-7714.13370

Ejemplares similares

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020)

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
por: Liu, Jingjing, et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors
por: Boumaza, Xavier, et al.
Publicado: (2022)

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
por: Wang, Jun, et al.
Publicado: (2023)

Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
por: Ren, Xiubao
Publicado: (2019)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
por: Dai, Xinlun, et al.
Publicado: (2020)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report
por: Li, Shuzhan, et al.
Publicado: (2022)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Liao, Juan-Yan, et al.
Publicado: (2021)

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
por: Liu, Xiaohang, et al.
Publicado: (2022)

Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents
por: Feng, Ying-Qi, et al.
Publicado: (2020)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

Recent Progress of Polymeric Corrosion Inhibitor: Structure and Application
por: Wang, Xuanyi, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Are we over-treating with checkpoint inhibitors?
por: Danson, Sarah, et al.
Publicado: (2019)

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
por: Zhao, Yu, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors
por: Liu, Fei, et al.
Publicado: (2022)

Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer
por: Zhang, Huaiyu, et al.
Publicado: (2021)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
por: Liu, Wenhui, et al.
Publicado: (2021)

Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors
por: Liu, Zhenzhen, et al.
Publicado: (2022)

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Jingwen, et al.
Publicado: (2021)

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review
por: Shen, Jingjing, et al.
Publicado: (2022)

Predictive Value of Max’s Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Qu, Yan, et al.
Publicado: (2021)

A Retrospective Study on Chronic Pelvic Pain Treated with Traditional Chinese Medicine Combined Therapy: 179 Cases (2016–2018)
por: Guo, Shanshan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Research progress in immune checkpoint inhibitors for lung cancer in China
por: Gan, Jiadi, et al.
Publicado: (2021)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Recurrent Pericardial Effusion in a Patient With Delayed Progression of Melanoma Treated With Immune Checkpoint Inhibitors
por: Valencia, Elsie A, et al.
Publicado: (2023)

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Xia, Shuang, et al.
Publicado: (2022)

Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors
por: Lyu, Jiahua, et al.
Publicado: (2023)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022)

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions
por: Yu, Yi-xuan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_alavfrckfumhb2jp7cu6npjo70